Physician profile
John Womack
NPI 1487693446
$930,889.59
in general payments reported to CMS, 2019-2025
14 companies · $134K in 2025
The $134K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $141K · 2020: $49K · 2021: $143K · 2022: $178K · 2023: $156K · 2024: $130K · 2025: $134K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $275K · Travel and Lodging: $88K · Consulting Fee: $39K · Food and Beverage: $17K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,125 · Education: $25.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $275,024.89 |
| Travel and Lodging | $87,748.94 |
| Consulting Fee | $39,125.00 |
| Food and Beverage | $16,673.87 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,125.00 |
| Education | $25.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $570,085.34 | 2022-2025 | Infuse, Infuse Multifocal, Zenlens |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $328,955.46 | 2019-2021 | |
| Coopervision INC. | $9,963.44 | 2019-2025 | Cvi Contact Lens, Clariti Contact Lens, Myday Contact Lens |
| Allergan, INC. | $9,244.33 | 2021-2022 | |
| Abbvie INC. | $8,341.43 | 2022-2023 | Vuity |
| Johnson & Johnson Vision Care, INC. | $3,188.39 | 2019-2025 | Acuvue |
| Alcon Vision LLC | $624.72 | 2019-2023 | Total30 |
| Sight Sciences, INC. | $218.55 | 2019-2021 | |
| Shire North American Group INC | $92.89 | 2019 | |
| Abb Con-Cise Optical Group LLC | $66.97 | 2019 | |
| Tarsus Pharmaceuticals, INC. | $44.17 | 2024 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $28.85 | 2020 | |
| Kala Pharmaceuticals, INC. | $18.86 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $16.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Womack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.